Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Denifanstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203051/0/en/Sagimet-s-License-Partner-Ascletis-Announced-Acceptance-of-New-Drug-Application-for-Denifanstat-for-the-Treatment-of-Moderate-to-Severe-Acne-by-China-s-National-Medical-Products-Ad.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Ascletis Announces China NMPA Acceptance of NDA for Denifanstat
    Ascletis Announces China NMPA Acceptance of NDA for Denifanstat

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-china-national-medical-products-administration-acceptance-of-new-drug-application-for-denifanstat-asc40-a-first-in-class-fasn-inhibitor-for-acne-treatment-302637708.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    Sagimet Biosciences Showcases Two Denifanstat Posters at AASLD
    Sagimet Biosciences Showcases Two Denifanstat Posters at AASLD

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184391/0/en/Sagimet-Biosciences-Presents-Two-Denifanstat-Posters-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Denifanstat Meets All Ph3 Endpoints in Moderate to Severe Acne
    Denifanstat Meets All Ph3 Endpoints in Moderate to Severe Acne

    24 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/24/3172712/0/en/Denifanstat-Achieved-All-Endpoints-in-the-Treatment-of-Moderate-to-Severe-Acne-in-Phase-3-Clinical-Trial-in-Acne-in-China-A-Presentation-at-the-2025-Fall-Clinical-Dermatology-Confe.html

    GLOBENEWSWIRE
    24 Oct 2025
    Share Share
    Ascletis Wraps Denifanstat (ASC40) Pre-NDA Consultation
    Ascletis Wraps Denifanstat (ASC40) Pre-NDA Consultation

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-completes-denifanstat-asc40-pre-nda-consultation-with-china-national-medical-products-administration-302583127.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Sagimet Biosciences To Present At AASLD Liver Meeting 2025
    Sagimet Biosciences To Present At AASLD Liver Meeting 2025

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162363/0/en/Sagimet-Biosciences-Announces-Upcoming-Presentation-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share